JP Morgan Private Wealth Advisors’s Protagenic Therapeutics Warrant PTIXW Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio PTIXW Stock Details PTIXW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25,000	Closed	-$600	–	1815
2023 Q1	$600	Buy	+25,000	New	+$1.29K	﹤0.01%	1928

Other funds holding PTIXW

WAM

Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

JP Morgan Private Wealth Advisors's PTIXW Position: Q2 2023 in Review

JP Morgan Private Wealth Advisors sold out of Protagenic Therapeutics Warrant (PTIXW) in Q2 2023, closing a stake of 25,000 shares — an estimated $600 sold.

JP Morgan Private Wealth Advisors first reported a position in PTIXW in Q1 2023 and held it in 1 quarter. The position peaked at $600 in Q1 2023. 2 funds tracked by Wall St. Rank hold PTIXW as of Q2 2023.

JP Morgan Private Wealth Advisors reported no remaining Protagenic Therapeutics Warrant position as of Q2 2023 after selling out during the quarter.
JP Morgan Private Wealth Advisors sold 25,000 Protagenic Therapeutics Warrant shares in Q2 2023, an estimated $600.
JP Morgan Private Wealth Advisors first reported a position in Protagenic Therapeutics Warrant in Q1 2023 and held it in 1 quarter.
JP Morgan Private Wealth Advisors's Protagenic Therapeutics Warrant position peaked at $600 in Q1 2023.
2 funds tracked by Wall St. Rank held Protagenic Therapeutics Warrant as of Q2 2023.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.